Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer

Purpose of Review T-cell immunoglobulin and ITIM domain (TIGIT) is a next-generation inhibitory receptor with multiple antibodies under exploration in cancer therapy. Here, we review the available data from the early trials and overview upcoming clinical trials on anti-TIGIT antibodies. Recent Findi...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2022-09, Vol.24 (9), p.1107-1112
Main Authors: Florou, Vaia, Garrido-Laguna, Ignacio
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Cancer
Clinical trials
Immune checkpoint
Immuno-oncology (RM Bukowski and JH Finke
Immunoglobulins
Immunotherapy
Lung cancer
Lymphocytes
Lymphocytes T
Medicine
Medicine & Public Health
Non-small cell lung carcinoma
Oncology
PD-1 protein
PD-L1 protein
Phosphorylation
Section Editors
Small cell lung carcinoma
Topical Collection on Immuno-oncology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review T-cell immunoglobulin and ITIM domain (TIGIT) is a next-generation inhibitory receptor with multiple antibodies under exploration in cancer therapy. Here, we review the available data from the early trials and overview upcoming clinical trials on anti-TIGIT antibodies. Recent Findings There is a promising activity of anti-TIGIT, particularly in combination with anti-PD-1/PD-L1 in non-small cell lung cancer (NSCLC) with already phase 3 trials currently ongoing to confirm these early findings. Summary Numerous anti-TIGIT antibodies are in clinical trials currently, and others are in preclinical development. Therefore, more data are expected in the next few years regarding the efficacy of this new checkpoint inhibitor in multiple solid and hematologic malignancies. However, preliminary data are promising, and anti-TIGIT treatment seems to confer more favorable responses when combined with anti-PD-1/anti-PD-L1 compared to either agent alone.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-022-01281-5